Message from
QiPharma R&D Japan
(Quick Impact Pharma R&D Japan)
Saving the lead time for “Go/ No-Go” decisions at each stage
of product development in Japan eventually resulting in abbr. NDA approaches
Offering drug development plans/ options/ strategies in Japan different from those within and outside a company
Providing cost-effective assistance (extensive research/ report
at low cost) for robust drug development plans together with a wide variety of development-related information from Japanese regulatory authorities or academia